Hikal Performance
- Today's Low
- ₹213
- Today's High
- ₹223
- 52 Week Low
- ₹146
- 52 Week High
- ₹373
- Open Price₹220
- Previous Close₹218
- Volume261,415
- 50 DMA₹196.50
- 100 DMA₹199.94
- 200 DMA₹222.55
Hikal Chart
Investment Returns
- Over 1 Month -1.43%
- Over 3 Month + 30%
- Over 6 Month -8.14%
- Over 1 Year -40.25%
Smart Investing Starts Here Start SIP with Hikal for Steady Growth!
Hikal Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- -54.3
- PEG Ratio
- 0.4
- Market Cap Cr
- 2,650
- P/B Ratio
- 2.2
- Average True Range
- 9.14
- EPS
- 2.94
- Dividend Yield
- 0.5
- MACD Signal
- 1.33
- RSI
- 63.13
- MFI
- 84.69
Latest Stock News Updates
Conference Call with Hikal Ltd. Management and Analysts on Q4FY26 & Full Year Performance and Outlook. Listen to the full earnings transcript.
- Trendlyne
- 4 weeks 2 days ago
Pharmaceuticals company Hikal announced Q4FY26 & FY26 results Consolidated Financial Highlights: Revenue from operations: Reported at Rs 5,194 million for Q4FY26, compared to Rs 5,524 million in Q4FY25, representing a YoY decrease of 5.97%. On a QoQ basis, it increased by 5.08% from Rs 4,943 million in Q3FY26. For FY26, revenue was Rs 17,126 million, down 7.91% YoY from Rs 18,598 million in FY25. Net Profit/Loss for the period: Reported a profit of Rs 144 million for Q4FY26, compared to Rs 502 million in Q4FY25 (YoY decrease of 71.31%). For FY26, the company reported a net loss of Rs 488 million, compared to a profit of Rs 908 million in FY25. Standalone Financial Highlights: Revenue from operations: Reported at Rs 5,194 million for Q4FY26, compared to Rs 5,524 million in Q4FY25 (YoY decrease of 5.97%). On a QoQ basis, it increased by 5.08% from Rs 4,943 million in Q3FY26. For FY26, revenue stood at Rs 17,126 million, a decrease of 7.91% YoY from Rs 18,598 million in FY25. Net Profit/Loss for the period: Reported a profit of Rs 146 million for Q4FY26, compared to Rs 503 million in Q4FY25 (YoY decrease of 70.97%). For FY26, the company reported a net loss of Rs 487 million, compared to a profit of Rs 909 million in FY25. Business Highlights: Segment-wise Performance: Pharmaceuticals: Revenue for Q4FY26 stood at Rs 2,916 million, compared to Rs 3,513 million in Q4FY25. For FY26, segment revenue was Rs 10,210 million. Crop Protection: Revenue for Q4FY26 stood at Rs 2,278 million, compared to Rs 2,011 million in Q4FY25. For FY26, segment revenue was Rs 6,916 million. Dividend: The Board recommended a final dividend of Rs 0.40 per equity share for the financial year 2025-26. Combined with the interim dividend of Rs 0.20 per share paid in March 2026, the total dividend aggregates to Rs 0.60 per equity share (30%). Appointment: Mr. Sandip Parikh (DIN: 00030990) was appointed as an Additional Director in the category of Independent Director for a period of 5 consecutive years, effective May 27, 2026. Result PDF
- Trendlyne
- 4 weeks 2 days ago
- Business Line
- 3 months 1 week ago
Hikal Financials
Hikal Technicals
EMA & SMA
- Bearish Moving Average 1
- Bullish Moving Average 15
- 20 Day
- ₹200.80
- 50 Day
- ₹196.50
- 100 Day
- ₹199.90
- 200 Day
- ₹222.60
Resistance and Support
- R3 230.94
- R2 226.97
- R1 220.95
- S1 210.96
- S2 206.99
- S3 200.97
Hikal Corporate Actions - Bonus, Splits, Dividends
About Hikal
- NSE Symbol
- HIKAL
- BSE Symbol
- 524735
- ISIN
- INE475B01022
Similar Stocks to Hikal
Popular Stocks
Hikal FAQs
Hikal share price is ₹214 As on 27 June, 2026 | 10:53
The Market Cap of Hikal is ₹2650.1 Cr As on 27 June, 2026 | 10:53
The P/E ratio of Hikal is -54.3 As on 27 June, 2026 | 10:53
The PB ratio of Hikal is 2.2 As on 27 June, 2026 | 10:53
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.